New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.

RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...

RSV season is beginning, but for the first time, parents can access an effective treatment to protect their infants from this common but dangerous virus.